Join Dr. Edgardo Santos and Dr. Luis Raez for a practical discussion on first-line decision-making in EGFR-mutated lung cancer and how early treatment choices shape survival, sequencing, and patient experience.

This episode explores why first-line therapy represents a critical window for long-term benefit, including the reality that many patients never reach later lines of treatment and the importance of early disease control. The speakers review guideline-supported first-line strategies, discuss how clinicians interpret survival and durability data, and examine the role of CNS disease as a key factor in treatment selection.

The conversation also addresses real-world implementation considerations, including adverse event management, administration and dosing factors, and how early patient education can improve treatment adherence and experience. Learn how interdisciplinary care teams provide proactive support to help optimize outcomes in the first months of therapy.

Tune in for key insights on optimizing first-line strategy and supporting patients from the start of therapy.

Join moderator Dr. Tiago Bianchi and an expert multidisciplinary panel, including Zilipah Cruz, MSN-RN, ONN-CG, Vanessa Sepulveda-Dominguez, RN, BSN, and Charlotte Martin, PharmD, for a deep dive into the essential non-clinical aspects of metastatic colorectal cancer (mCRC) care.

This episode explores the critical role of the entire oncology team in addressing the Social Determinants of Health (SDOH) and supporting patient survivorship.

Key Challenges & Team Coordination: The panel will discuss the reality of holistic patient support, drawing on survey findings:

• SDOH Screening Gaps: While 68% of clinicians report screening for SDOH, most are not using standardized tools, leading to inconsistent identification of patient needs.
• Support & Barriers: Despite 90% of teams reporting access to support resources (e.g., nurse navigation, pharmacy, social work), implementation varies. The top real-world barriers remain insurance, transportation, patient education, and cost.
• The Interdisciplinary Team: Hear how RNs, APPs, PharmDs, and Navigators coordinate care, from assessing SDOH to integrating screening into the EHR, to provide seamless support.

Unique Survivorship Concerns: The conversation addresses the unique survivorship challenges faced by younger mCRC patients, including:

• Managing fertility and sexual health concerns.
• Facilitating the return to work and maintaining career stability.
• The importance of clear patient education, communication, and managing treatment expectations to improve long-term quality of life.

Tune in for a vital discussion on how care teams move beyond clinical treatment to provide comprehensive, coordinated support for the whole mCRC patient.

The mCRC Journey: Treatment Sequencing and Real-World Decisions (Epi. 2)

Join medical oncologists Dr. Tiago Bianchi and Dr. Raji Shameem for Episode 2 of our "Voices in Colorectal Cancer" Series as they navigate the complex, guideline-based, and real-world treatment landscape for metastatic colorectal cancer (mCRC).

This episode delves into current practice, informed by key insights from a recent FLASCO survey:

• Molecular Profiling: The doctors confirm molecular profiling is widely adopted (86% of respondents test patients >90% of the time). However, they discuss persistent gaps related to insurance barriers and challenges with specimen quality.
• Sequencing Strategies: Explore the current NCCN mCRC treatment pathways and the variety in real-world sequencing decisions after initial chemotherapy. The discussion contrasts community versus academic approaches to later-line decision-making.
• New Horizons: Learn where biomarker-agnostic therapies fit into the mCRC journey and how novel treatments are integrated into existing protocols.
• Access & Trials: The doctors address common access issues, prior authorization, and payer challenges that complicate care. Finally, they discuss the critical—yet often delayed—process of clinical trial referral, highlighting timing and lack of awareness as the primary barriers.

Tune in to understand the complexities of mCRC management, from biomarker testing to strategic sequencing and overcoming systemic access hurdles.